AGL 24.24 Increased By ▲ 0.77 (3.28%)
AIRLINK 107.70 Increased By ▲ 1.59 (1.5%)
BOP 5.12 Decreased By ▼ -0.05 (-0.97%)
CNERGY 3.63 Decreased By ▼ -0.03 (-0.82%)
DCL 7.32 Decreased By ▼ -0.48 (-6.15%)
DFML 42.10 Decreased By ▼ -2.09 (-4.73%)
DGKC 88.80 Increased By ▲ 0.30 (0.34%)
FCCL 21.75 No Change ▼ 0.00 (0%)
FFBL 41.85 Decreased By ▼ -0.67 (-1.58%)
FFL 8.61 Decreased By ▼ -0.14 (-1.6%)
HUBC 148.75 Increased By ▲ 0.95 (0.64%)
HUMNL 10.14 Decreased By ▼ -0.11 (-1.07%)
KEL 4.28 Decreased By ▼ -0.06 (-1.38%)
KOSM 3.59 Decreased By ▼ -0.20 (-5.28%)
MLCF 36.20 Decreased By ▼ -0.20 (-0.55%)
NBP 47.75 Decreased By ▼ -1.55 (-3.14%)
OGDC 129.10 Decreased By ▼ -1.75 (-1.34%)
PAEL 25.75 Decreased By ▼ -0.20 (-0.77%)
PIBTL 6.00 Decreased By ▼ -0.05 (-0.83%)
PPL 113.65 Decreased By ▼ -0.90 (-0.79%)
PRL 22.30 Decreased By ▼ -0.30 (-1.33%)
PTC 12.10 Decreased By ▼ -0.27 (-2.18%)
SEARL 54.98 Decreased By ▼ -0.72 (-1.29%)
TELE 7.11 Decreased By ▼ -0.14 (-1.93%)
TOMCL 37.11 Increased By ▲ 0.71 (1.95%)
TPLP 7.76 Decreased By ▼ -0.19 (-2.39%)
TREET 15.00 Decreased By ▼ -0.29 (-1.9%)
TRG 55.54 Decreased By ▼ -1.16 (-2.05%)
UNITY 31.20 Decreased By ▼ -0.65 (-2.04%)
WTL 1.15 Decreased By ▼ -0.02 (-1.71%)
BR100 8,248 Decreased By -46.7 (-0.56%)
BR30 25,878 Decreased By -223.8 (-0.86%)
KSE100 78,030 Decreased By -439.8 (-0.56%)
KSE30 25,084 Decreased By -114.2 (-0.45%)

The US Food and Drug Administration has extended by three months its review of Regeneron Pharmaceuticals Inc’s application for the full approval of its COVID-19 antibody therapy, the US drugmaker said on Thursday.

Before making its decision, the health agency wants to look at additional data submitted by Regeneron on using the antibody cocktail as a preventive treatment.

The FDA has not asked for any extra studies to complete its review and will now decide on the drug by July 13, Regeneron said.

AstraZeneca pays $775mn to settle drug dispute with Japan’s Chugai

Regeneron’s “cocktail” of two monoclonal antibodies, casirivimab and imdevimab, had received an emergency use authorization in the United States in late 2020 to treat patients who were 12 years and older with mild-to-moderate COVID-19.

The therapy, called REGEN-COV, was later also authorized in the country for the prevention of COVID-19 in certain people exposed to an infected individual, or who were at high risk of such exposure.

However, data showed that REGEN-COV and a rival monoclonal antibody drug from Eli Lilly were unlikely to be effective against the highly contagious Omicron coronavirus variant. That led the US FDA to revise the emergency use authorizations for both therapies to limit their use.

Pfizer-BioNTech seek US approval of second Covid booster for 65+

Regeneron is collaborating with Roche, which is primarily responsible for the development and distribution of the treatment outside the United States.

Comments

Comments are closed.